MediGene AG
Lochhamer Str. 11
Martinsried
82152
Germany
Tel: 49-89-85 65 29-00
Fax: 49-89-85 65 29-20
Website: http://www.medigene.de/
Email: medigene@medigene.de
285 articles about MediGene AG
-
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
3/29/2023
Medigene AG, an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the year ended December 31, 2022 and provided a corporate update.
-
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
3/28/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023.
-
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
3/20/2023
Medigene AG, an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced the appointment of Kirsty Crame, MD as Vice President, Head of Clinical Research & Development.
-
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
3/16/2023
Medigene AG will present a poster at the American Association for Cancer Research Virtual Annual Meeting 2023 being held on April 14-19, 2023.
-
Medigene AG to report full year 2022 financial results on March 29, 2023
3/15/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023.
-
Medigene Amends 2022 Financial Guidance
3/10/2023
The Executive Management Board of Medigene AG, an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, adjusted financial guidance for fiscal year 2022.
-
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
2/23/2023
Medigene AG has been invited to present at the CAR-TCR Summit in London on February 23, 2023, on the topic “Implementing Automation & Innovation to Improve Manufacturing of TCR-T Cells.
-
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
2/22/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023.
-
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
2/15/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 6th Annual CAR-TCR Summit Europe in London from February 21 to 23, 2023.
-
Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
2/1/2023
Medigene AG announced the appointment of Pamela Keck as Vice President, Head of Investor Relations and Corporate Communications.
-
Medigene Receives $3 Million Milestone Payment from 2seventy bio
1/18/2023
Medigene AG announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future.
-
Medigene Announces Strategy and Corporate Update
11/15/2022
Medigene AG announces an updated corporate strategy to drive and expedite the development of novel therapies for the treatment of multiple solid tumor indications with high unmet need.
-
Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
1/5/2021
Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The pane
-
Clinical Catch-Up: June 22-26
6/29/2020
It was a busy week for clinical trial updates. Here’s a look. -
Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
6/23/2020
Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has received approval from the Dutch regulatory authority (the Central Committee on Research Involving Human Subjects, CCMO) to begin a first clinical trial of MDG1021.
-
Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid TumorsPoster presentation at the AACR Virtual Annual Meeting II, 22 – 24 June 2020
6/22/2020
Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, presents insights from preclinical studies on its PD1-41BB switch receptor at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place from 22 – 24 June 2020. The e-poster is available online today on the first day of the virtual conference as well as
-
Medigene Provides Results for Fiscal Year 2019 and OutlookConference call on 26 March 2020 at 4pm CET (Frankfurt) / 11am EDT (New York)
3/26/2020
Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, published its financial results and Annual Report for the 2019 financial year and its outlook for the current 2020 financial year.
-
IRICoR, Universite de Montreal and Medigene sign collaboration and exclusive licensing option on novel cancer antigens
1/30/2020
UdeM's research team, will provide Medigene with tumor-specific antigens (TSAs) which they discovered using their proprietary platform, as novel targets for various cancer indications, particularly for solid tumors.
-
Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients
1/10/2020
Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today publishes topline results from its completed open-label Phase I/II clinical trial of Medigene’s autologous dendritic cell (DC) vaccine in 20 patients with acute myeloid leukemia (AML)
-
Medigene AG: Interim 1-year clinical immune monitoring data from DC vaccine trial in AML presented at ASH 2019 Annual Meeting
12/10/2019
Munich/ Martinsried Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that Medigene's researchers presented clinical immune monitoring data obtained during the first year of treatment from the ongoing Phase I/II clinical trial with Medigene's DC vaccine for the treatment of acute myeloid leukemia at the 61st ASH Annual Meeting.